196 related articles for article (PubMed ID: 35173547)
1. HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer.
Dou Z; Qiu C; Zhang X; Yao S; Zhao C; Wang Z; Chu R; Chen J; Chen Z; Li R; Wang K; Liu P; Liu C; Song K; Kong B
Int J Biol Sci; 2022; 18(3):1188-1210. PubMed ID: 35173547
[TBL] [Abstract][Full Text] [Related]
2. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.
Matheson CJ; Venkataraman S; Amani V; Harris PS; Backos DS; Donson AM; Wempe MF; Foreman NK; Vibhakar R; Reigan P
ACS Chem Biol; 2016 Apr; 11(4):921-30. PubMed ID: 26745241
[TBL] [Abstract][Full Text] [Related]
3. Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis.
Chen D; Lin X; Gao J; Shen L; Li Z; Dong B; Zhang C; Zhang X
Biomed Res Int; 2018; 2018():5813292. PubMed ID: 29977914
[TBL] [Abstract][Full Text] [Related]
4. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.
Yang Z; Liao J; Lapidus RG; Fan X; Mehra R; Cullen KJ; Dan H
Cancer Chemother Pharmacol; 2022 Apr; 89(4):469-478. PubMed ID: 35212780
[TBL] [Abstract][Full Text] [Related]
5. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
[TBL] [Abstract][Full Text] [Related]
6. ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models.
Li J; Lu J; Xu M; Yang S; Yu T; Zheng C; Huang X; Pan Y; Chen Y; Long J; Zhang C; Huang H; Dai Q; Li B; Wang W; Yao S; Pan C
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36378528
[TBL] [Abstract][Full Text] [Related]
7. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
Fu J; Cai H; Wu Y; Fang S; Wang D
Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
[TBL] [Abstract][Full Text] [Related]
8. TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway.
Qi G; Ma H; Li Y; Peng J; Chen J; Kong B
Cell Death Dis; 2021 Dec; 12(12):1135. PubMed ID: 34876569
[TBL] [Abstract][Full Text] [Related]
9. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
10. Increased Expression of Holliday Junction-Recognizing Protein (HJURP) as an Independent Prognostic Biomarker in Advanced-Stage Serous Ovarian Carcinoma.
Li L; Li X; Meng Q; Khan AQ; Chen X
Med Sci Monit; 2018 May; 24():3050-3055. PubMed ID: 29743473
[TBL] [Abstract][Full Text] [Related]
11. HJURP inhibits proliferation of ovarian cancer cells by regulating CENP-A/CENP-N.
Zhang Y; Zhang W; Sun L; Yue Y; Shen D; Tian B; Du M; Dong M; Liu Y; Zhang D
Bull Cancer; 2022 Oct; 109(10):1007-1016. PubMed ID: 35940943
[TBL] [Abstract][Full Text] [Related]
12. Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.
Kim HY; Cho Y; Kang H; Yim YS; Kim SJ; Song J; Chun KH
Oncotarget; 2016 Aug; 7(31):49902-49916. PubMed ID: 27363019
[TBL] [Abstract][Full Text] [Related]
13. Transcription factor KLF2 enhances the sensitivity of breast cancer cells to cisplatin by suppressing kinase WEE1.
Li R; Chen J; Gao X; Jiang G
Cancer Biol Ther; 2021 Sep; 22(7-9):465-477. PubMed ID: 34486497
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.
Liu MX; Siu MK; Liu SS; Yam JW; Ngan HY; Chan DW
Oncotarget; 2014 Feb; 5(4):944-58. PubMed ID: 24659709
[TBL] [Abstract][Full Text] [Related]
15. Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine.
Moreira DC; Venkataraman S; Subramanian A; Desisto J; Balakrishnan I; Prince E; Pierce A; Griesinger A; Green A; Eberhardt CG; Foreman NK; Vibhakar R
J Neurooncol; 2020 May; 147(3):531-545. PubMed ID: 32180106
[TBL] [Abstract][Full Text] [Related]
16. TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer.
Liu Y; Zhu K; Guan X; Xie S; Wang Y; Tong Y; Guo L; Zheng H; Lu R
J Ovarian Res; 2021 Oct; 14(1):128. PubMed ID: 34598710
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Bang JH; Oh KS; Seo HR; Oh DY; Bang YJ
Cancer Res Treat; 2020 Jul; 52(3):945-956. PubMed ID: 32311864
[TBL] [Abstract][Full Text] [Related]
19. Involvement of ATMIN-DYNLL1-MRN axis in the progression and aggressiveness of serous ovarian cancer.
Berkel C; Cacan E
Biochem Biophys Res Commun; 2021 Sep; 570():74-81. PubMed ID: 34273621
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
Murakami K; Kita Y; Sakatani T; Hamada A; Mizuno K; Nakamura K; Takada H; Matsumoto K; Sano T; Goto T; Akamatsu S; Saito R; Tsuruyama T; Ogawa O; Kobayashi T
Cancer Sci; 2021 Sep; 112(9):3669-3681. PubMed ID: 34212455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]